Gregory F. Heath
Direktor/Vorstandsmitglied bei numares AG
Profil
Gregory F.
Heath is a Member-Supervisory Board at numares AG since 2022.
Previously, he worked as Head-Business Development at F.
Hoffmann-La Roche Ltd.
from 2000 to 2003, Senior VP-Global Molecular Diagnostics Business at Roche Molecular Systems, Inc. from 2004 to 2008, and Senior VP & General Manager-Diagnostics at Illumina, Inc. in 2011.
He holds a graduate degree from Hollins University Corp., an undergraduate degree from Illinois State University, and a doctorate degree from Virginia Commonwealth University.
Aktive Positionen von Gregory F. Heath
| Unternehmen | Position | Beginn |
|---|---|---|
numares AG
 numares AG Medical SpecialtiesHealth Technology numares AG develops and markets new analytic and diagnostic tests based on nuclear magnetic resonance spectroscopy. It offers in-vitro-diagnostic tests with the CE marking for high-throughput use in clinical practice and medical research. The firm?s test applications provide valuable information on the disease status of patients in the indication areas of cardiovascular diseases, nephrology and oncology. The company was founded in April 2004 and is headquartered in Regensburg, Germany. | Direktor/Vorstandsmitglied | 01.01.2022 |
Ehemalige bekannte Positionen von Gregory F. Heath
| Unternehmen | Position | Ende |
|---|---|---|
Roche Molecular Systems, Inc.
 Roche Molecular Systems, Inc. Medical/Nursing ServicesHealth Services Roche Molecular Systems, Inc. develops and produces molecular-based diagnostic tests and automated testing platforms. It specializes in oncology, virology, microbiology and blood screening tests areas. The firm's customers include researchers, physicians, patients, hospitals, laboratories and blood banks. The company is headquartered in Pleasanton, CA. | Corporate Officer/Principal | 01.01.2008 |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | 02.01.2003 |
| ILLUMINA, INC. | Corporate Officer/Principal | - |
Ausbildung von Gregory F. Heath
| Illinois State University | Undergraduate Degree |
| Hollins University Corp. | Graduate Degree |
| Virginia Commonwealth University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ILLUMINA, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Health Technology |
Roche Molecular Systems, Inc.
Roche Molecular Systems, Inc. Medical/Nursing ServicesHealth Services Roche Molecular Systems, Inc. develops and produces molecular-based diagnostic tests and automated testing platforms. It specializes in oncology, virology, microbiology and blood screening tests areas. The firm's customers include researchers, physicians, patients, hospitals, laboratories and blood banks. The company is headquartered in Pleasanton, CA. | Health Services |
numares AG
numares AG Medical SpecialtiesHealth Technology numares AG develops and markets new analytic and diagnostic tests based on nuclear magnetic resonance spectroscopy. It offers in-vitro-diagnostic tests with the CE marking for high-throughput use in clinical practice and medical research. The firm?s test applications provide valuable information on the disease status of patients in the indication areas of cardiovascular diseases, nephrology and oncology. The company was founded in April 2004 and is headquartered in Regensburg, Germany. | Health Technology |
